Information Provided By: 
Fly News Breaks for May 11, 2018
RARE
May 11, 2018 | 05:12 EDT
Barclays analyst Gena Wang upgraded Ultragenyx Pharmaceutical to Overweight and raised her price target for the shares to $74 from $62. The analyst thinks a higher price target for Crysvita could drive upside to revenue growth expectations. She also sees a "reasonable probability of success" for triheptanoin in long-chain fatty acid oxidation disorde and glucose transporter type-1 deficiency syndrome.
News For RARE From the Last 2 Days
